- Home
- JCTC vs NXTC Comparison
JCTC vs NXTC Comparison
Compare JCTC & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JCTC
- NXTC
- Stock Information
- Founded
- JCTC 1953
- NXTC 2015
- Country
- JCTC United States
- NXTC United States
- Employees
- JCTC N/A
- NXTC N/A
- Industry
- JCTC
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- JCTC
- NXTC Health Care
- Exchange
- JCTC NYSE
- NXTC Nasdaq
- Market Cap
- JCTC 12.5M
- NXTC 13.9M
- IPO Year
- JCTC 1996
- NXTC 2019
- Fundamental
- Price
- JCTC $3.77
- NXTC $0.47
- Analyst Decision
- JCTC
- NXTC Strong Buy
- Analyst Count
- JCTC 0
- NXTC 2
- Target Price
- JCTC N/A
- NXTC $3.50
- AVG Volume (30 Days)
- JCTC 5.0K
- NXTC 129.8K
- Earning Date
- JCTC 07-14-2025
- NXTC 05-01-2025
- Dividend Yield
- JCTC N/A
- NXTC N/A
- EPS Growth
- JCTC N/A
- NXTC N/A
- EPS
- JCTC N/A
- NXTC N/A
- Revenue
- JCTC $47,432,094.00
- NXTC N/A
- Revenue This Year
- JCTC N/A
- NXTC N/A
- Revenue Next Year
- JCTC N/A
- NXTC N/A
- P/E Ratio
- JCTC N/A
- NXTC N/A
- Revenue Growth
- JCTC N/A
- NXTC N/A
- 52 Week Low
- JCTC $3.26
- NXTC $0.22
- 52 Week High
- JCTC $5.69
- NXTC $1.82
- Technical
- Relative Strength Index (RSI)
- JCTC N/A
- NXTC 51.39
- Support Level
- JCTC N/A
- NXTC $0.47
- Resistance Level
- JCTC N/A
- NXTC $0.52
- Average True Range (ATR)
- JCTC 0.00
- NXTC 0.04
- MACD
- JCTC 0.00
- NXTC 0.00
- Stochastic Oscillator
- JCTC 0.00
- NXTC 48.91
About JCTC JEWETT-CAMERON TRADING CO
Jewett-Cameron Trading Co Ltd through its subsidiaries engages in the wholesale distribution of a variety of specialty wood products. Its operating segments include, The Industrial wood products segment is engaged in the processing and distribution of industrial wood products. The Pet Fencing and Other segment, which is the key revenue driver, operates as a wholesaler of wood products and a manufacturer and distributor of specialty metal products. The Seed processing and sales segment processes and distributes agricultural seed and Corporate and administrative. The company predominantly operates in the United States and also has a presence in Canada, Latin America, Europe and Asia Pacific, and other regions.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.